Basilea Pharmaceutica International Ag

Martin Stieger

Jens Pohlmann

Heidi Lane

Stefan Reinelt

Disclosed are compounds of formula (I) wherein A is CH or N, B is CR or N; and D is CR; R represents hydrogen, OH or NH; R1 and R2, independently of each other, represent hydrogen, N(R3), halogen, cyano, nitro, R4-C1-C4alkyl, R4-C1-C4halogenoalkyl, OH, R4-C1-C4alkoxy, R4-C1-C4halogenoalkoxy, SH, R4-C1-C4alkythio, R4-C1-C4halogenoalkylthio; R3 represents, independently at each occurrence, hydrogen, R4-C1-C4alkyl or R4-C1-C4halogenoalkyl; R3a represents, independently at each occurrence, hydrogen or C1-C4 alkyl; R4 represents, independently at each occurrence, hydrogen, halogen, cyano, OH, SH, NH, NH(CH) or N(CH); X represents a group of formula -E- or -E-F&#x2014;, wherein E and F are different from each other and represent a group selected from &#x2014;C(R3a)2-, &#x2014;(C&#x2550;O)&#x2014;, &#x2014;NR3a- and &#x2014;O&#x2014; and F is linked to Y, with the proviso that if X represents -E-F&#x2014; one of E or F represents &#x2014;C(R3a)- or &#x2014;(C&#x2550;O)&#x2014;; Y represents a group selected from C1-C6alkyl, mono- or bicyclic C3-C11cycloalkyl, which may be partially unsaturated, mono- or bicyclic 3 to 11-membered heterocycloalkyl, which may be partially unsaturated, a mono- or bicyclic group comprising at least one aryl or heteroaryl cycle, wherein said heterocycloalkyl group and said group comprising at least one heteroaryl cycle comprise one or more heteroatoms selected from nitrogen, oxygen and sulfur and said group Y is either unsubstituted or substituted by one or more substituents and comprises including its substituents one or more than one nitrogen atom having a lone electron pair; and Z represents a mono- or bicyclic group comprising at least one aryl or heteroaryl cycle, said heteroaryl cycle comprising one or more heteroatoms selected from nitrogen, oxygen and sulfur, which aryl or heteroaryl group is unsubstituted or substituted by one or more substituents; including tautomers of said compounds, mixtures of two tautomeric forms of said compounds, and pharmaceutically acceptable salts of said compounds, tautomers thereof or mixtures of two tautomeric forms thereof, preferably with the proviso that Y comprises one or more primary amino group &#x2014;NH, when X represents &#x2014;(C&#x2550;O)&#x2014; or &#x2014;(C&#x2550;O)&#x2014;NR3a-, wherein R3a represents hydrogen or C1-C4alkyl; which are useful for the treatment of proliferation disorders or diseases, such as cancer. 

Growing community of inventors

Basel, Switzerland

Martin Stieger